MDGL - NASDAQ
Madrigal Pharmaceuticals, Inc.
$488.15
+7.8%Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
At a Glance
Live SnapshotMadrigal Pharmaceuticals, Inc. Management Team
Mr. William J. Sibold
Chief Executive Officer, President & Director
Compensation
$1,850,446
Ms. Tina E. Ventura
Chief Investor Relations Officer
Ms. Carole Huntsman
Executive Vice President & Chief Commercial Officer
Compensation
$870,825
Ms. Mardi C. Dier
Executive Vice President & Chief Financial Officer
Compensation
$934,681
Mr. Clint Wallace
Executive Vice President & Chief Human Resources Officer
Mr. Ronald Filippo
Executive Vice President & Chief Information Officer
Mr. Mark Underwood
Executive Vice President of Business Planning & Operations
Ms. Shannon Kelley
Executive Vice President, Chief Legal Officer & Corporate Secretary
Compensation
$782,208
Dr. Rebecca A. Taub M.D.
Founder, Senior Scientific & Medical Advisor and Director
Compensation
$1,072,209
Mr. Edward Chiang
Senior Vice President of Clinical & Technical Operations
Madrigal Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $245K and sold $13.11M worth of MDGL shares, resulting in $12.86M of net selling activity.
3 Months
0
0.00
2.6K
1.25M
-1.3M
-$1.25M
3-6 Months
0
0.00
2.7K
1.30M
-1.3M
-$1.30M
6-9 Months
0
0.00
11.0K
5.34M
-5.3M
-$5.34M
9-12 Months
657
245.24K
14.3K
5.22M
-5.0M
-$4.98M
Top Buyers
Baker Bros. Advisors Lp
Director
$245K
Top Sellers
Sibold William John
Director, Officer: President And Ceo
$5.08M
Friedman Paul A
Director
$3.54M
Taub Rebecca
Director
$1.38M
Dier Mardi
Officer: Evp And Cfo
$967K
Soergel David
Officer: Chief Medical Officer
$952K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $12.86M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
MDGL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 20, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 25, 2024 | 2024 | |
DEF 14A DEF 14A N/A | May 01, 2023 | May 01, 2023 | ||
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 17, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 17, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | May 15, 2019 | June 27, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 27, 2018 | June 19, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 29, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.